AI deals won, but organic growth stalled at 2%—and management's claim doesn't hold water

On the surface, LTTS delivered a blowout quarter: PAT up 67%, EBIT margins at 16.3% and ahead of the prior 16–17% target, and a massive deal backlog of $203 million. The problem is what those numbers hide. Strip away the ₹165 crore one-time SWC divestment gain and adjusted PAT is only up 17%. Strip away the helpful segments—Sustainability grew 13.4% YoY and now props 30% of revenue—and the core business is barely growing. And when you dig into management's actual claim on the call, the real gap opens up: they asserted 4.8% YoY revenue growth in constant currency. The company delivered 2%. That's a 140% overstatement.

LTTS reported PAT of ₹549 crore. Of that, ₹165 crore came from the completed sale of SWC (a now-divested subsidiary). That is 30% of the reported profit. The remaining ₹384 crore is organic—a 17% year-on-year increase, not the 67% headline suggests. The gap matters because it separates genuine operational leverage from portfolio surgery. Management knew the SWC gain was coming; they did not adjust guidance upward on the back of it. That restraint is telling.

On the earnings call, management stated that LTTS achieved 4.8% year-on-year revenue growth in constant currency. The delivered Q2 result shows 2.0% YoY growth in reported rupees. Even adjusting for FX headwinds (~0.8%), a 1–2 percentage-point gap is not margin of error; it suggests either a modeling error in management's claim or a promotional tone that oversells the quarter. This is not a minor detail. When a company claims 4.8% and delivers 2%, it erodes credibility on forward guidance—and LTTS is asking the market to believe a 13–15% CAGR over the next five years.

Three material shifts from Q1's narrative emerge in Q2: AI revenue quantified for the first time. Q1 positioned AI as strategic priority; Q2 disclosed $120 million annualized Engineering Intelligence (EI) revenue, roughly 9.5% of the quarterly run-rate, with >50% of the $203 million deal backlog AI-led. The specificity helps, but also reveals the gap between AI buzz and actual scale: $120 million on ₹3,040 crore is material but not transformational. AI margins are premium, which helps offset the lumpiness. Europe Auto recovery pushed to 9–12 months. Q1 implied recovery was near; Q2 acknowledges 'headwinds' in Europe Auto (part of the Mobility segment) and now flags a 9–12 month recovery timeline. OEMs are in strategy reset (EV transition, cost restructuring). This is a downgrade in timing, not fundamentals. Tech segment growth deferred to Q4. Q1 guided Tech return to growth from Q2 onwards. Q2 reality: Tech is stable/muted. Med Tech saw a program ramp-down in Q2 extending into Q3, with restart and growth pushed to Q4 and beyond. Management signalled this in real-time but it represents a miss on Q1's guidance.

The stock trades at ₹3,910, above its 20-, 50-, and 200-day moving averages, signalling technical strength. RSI is 69.4 (neutral, not overbought). But the bigger picture is significant: LTTS is down 34.83% from its all-time high, though up 29.91% off the 52-week low—indicating a recovery underway but not yet a rebound to confidence. Ownership tells a cautious story. FII shareholding has slipped to 4.12% from 4.67% a year ago—a 55 basis-point trim. DII is stable at 14.05%; promoter is steady at 73.52%. The consistent FII trim suggests institutional investors are underweighting the stock, waiting for proof of execution rather than panic selling or enthusiasm. Volume is increasing, which could indicate selective accumulation, but paired with FII trimming and neutral technicals, the market message is clear: "Show us you can convert deals and accelerate growth before we re-rate." The valuation—down 35% from ATH but still near technical support—reflects rational caution on a company reaffirming 13–15% CAGR while delivering 2% organic growth.

Forget the reported PAT; focus on adjusted organic revenue growth. The SWC gain is history. Watch Q3 and Q4 organic growth rate (excluding one-time items) and whether it re-accelerates toward the 5–7% range that would justify the 13–15% CAGR target over time. If organic growth stays at 2–3%, the long-term guidance is not credible. LTTS has the assets (margins, deals, partnerships) to deliver; execution and conversion pace are the gating items.